These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 13414855)

  • 1. [Pharmacological properties of some new coronary dilators, particularly of flavone-7-ethyl-oxyacetate].
    SETNIKAR I; ZANOLINI T
    Farmaco Sci; 1956; 11(10):855-82. PubMed ID: 13414855
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new coronary vasodilator: flavone-7-hydroxy ethyl acetate].
    MARRAMA P; VECCHI GP
    Folia Cardiol; 1956 Aug; 15(4):419-34. PubMed ID: 13375735
    [No Abstract]   [Full Text] [Related]  

  • 3. [PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A CORONARY VASODILATOR: ETHYL FLAVONE-7-OXYACETATE].
    MORIN H; ROUX M; JACHIET MT
    Therapie; 1964; 19():1555-68. PubMed ID: 14242727
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study on the effect of ethyl flavone-7-oxyacetate in 34 cases of angina pectoris].
    CESARMAN VITIS T; GIORDANO M
    Prensa Med Mex; 1962; 27():343-6. PubMed ID: 14019765
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of flavone-7-hydroxyethylactate in angina pectoris].
    MASONI A; FINZI CM
    Minerva Med; 1957 Nov; 48(93):3908-14. PubMed ID: 13503875
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacological studies on flavone-7-ethyl oxyacetate].
    KANDA Z; SEKIYA A; KONO C
    Nihon Yakurigaku Zasshi; 1962 Nov; 58():459-66. PubMed ID: 13962164
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ethyl-7-hydroxyaceto-flavone (recordil) in the therapy of angina pectoris and its effects on hemodynamics and renal function].
    STRAUSAK A; COTTIER P; SCHMID A
    Cardiologia (Basel); 1959; 34(2):138-46. PubMed ID: 13629509
    [No Abstract]   [Full Text] [Related]  

  • 8. The coronary vasodilator activity of morpholinoethyl-3-methyl-flavone-8-carboxylate in comparison with that of other coronary vasodilators.
    SETNIKAR I; MURMANN W; RAVASI MT
    Arch Int Pharmacodyn Ther; 1961 Apr; 131():187-208. PubMed ID: 13750386
    [No Abstract]   [Full Text] [Related]  

  • 9. [Research on coronary dilators in the chromone group; ethyl esters and basic esters of chromone-hydroxyacetic acid and flovone-jydroxyacetic acid].
    DA RE P; COLLEONI A; SETNIKAR I
    Farmaco Sci; 1958; 13(8):561-73. PubMed ID: 13574215
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect on lipid metabolism of a coronary dilator: ethyl-7-oxyacetate flavone].
    Dupont JC; Sambin P; Detry R; Pont M
    Lyon Med; 1969 Apr; 221(16):941-7. PubMed ID: 5398694
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analytic research on ethyl flavone-7-hydroxyacetate].
    BELLOMONTE G; CARDINI C
    Rend Ist Sup Sanit; 1959; 22():613-8. PubMed ID: 13798602
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical study on flavone-7-hydroxyethylacetate in coronary insufficiency.
    SCHWARTZ A; MARKMAN A; PORTUGAL OP; PFEFERMAN A
    Arq Bras Cardiol; 1959 Sep; 12():205-14. PubMed ID: 14443956
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of ethyl flavone-7-oxyacetate with long-term action in acute coronary insufficiency].
    Mathivat A; Epois A; Melman S
    Cah Med; 1970 Oct; 12(13):1141-3. PubMed ID: 5523288
    [No Abstract]   [Full Text] [Related]  

  • 14. [The importance of the analysis of data in the evaluation of coronary dilators].
    BECCARI E
    Farmaco Sci; 1956; 11(11):947-52. PubMed ID: 13414861
    [No Abstract]   [Full Text] [Related]  

  • 15. Coronary vasodilating drugs.
    WILLIS PW; DUFF IF
    Med Clin North Am; 1957 Mar; 41(2):449-69. PubMed ID: 13407229
    [No Abstract]   [Full Text] [Related]  

  • 16. [Once more about coronary dilators; comments on the answer of Professor I. Setnikar].
    BECCARI E
    Farmaco Sci; 1957; 12(1):49-50. PubMed ID: 13414875
    [No Abstract]   [Full Text] [Related]  

  • 17. Failure of many new heart-failure drugs: the need for vasoconstrictor rather than vasodilator agents?
    Cleland JG
    Br J Hosp Med; 1994 Sep 7-20; 52(5):193, 195-6. PubMed ID: 7820314
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of a coronary vessel dilating drug (flavone-7-hydroxyethylacetate) on the abnormal phase of repolarization in Wolff-Parkinson-White syndrome].
    CATUREGLI L; MASSEI G
    Folia Cardiol; 1958 Oct; 17(5):441-56. PubMed ID: 13619891
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of chronic angina with ethyl-flavone-7-oxyacetate].
    Soulié P; Gaudeau S
    Coeur Med Interne; 1971; 10(2):301-4. PubMed ID: 5568275
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of flavon-7-ethyl oxyacetate on the cardiovascular system].
    Takenaka F; Takeya N; Tazume Y; Hayakawa T; Sakai M
    Kumamoto Igakkai Zasshi; 1967 Sep; 41(9):843-8. PubMed ID: 5631463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.